Access comprehensive financial analyses and make smarter investments - get the Manual of Investments on Amazon!

Tango Therapeutics Reports $343 Million Cash Position

Tango Therapeutics, Inc. (NASDAQ: TNGX) has reported its financial results for the fourth quarter and full year ended December 31, 2025, and provided business highlights. The company's cash position as of December 31, 2025, was $343 million, providing a runway into 2028 beyond anticipated key data inflection points.

In terms of collaboration revenue, the company reported $0 for the three months ended December 31, 2025, compared to $5.4 million for the same period in 2024. For the twelve months ended December 31, 2025, collaboration revenue was $62.4 million, compared to $30.0 million for the same period in 2024.

Regarding license revenue, there was no revenue for the three and twelve months ended December 31, 2025, compared to $0 and $12.1 million for the same periods in 2024, respectively. The company recognized license revenue in the second quarter of 2024 primarily due to licensing a drug discovery program to Gilead for $12.0 million during the period.

Research and development expenses were $32.1 million for the three months ended December 31, 2025, compared to $31.3 million for the same period in 2024. For the twelve months ended December 31, 2025, research and development expenses were $132.2 million, compared to $143.9 million for the same period in 2024. The year-over-year change was due to decreased spend on discontinued clinical programs as well as lower expenses for certain programs, partially offset by increased spend for the advancement of specific programs.

General and administrative expenses were $9.8 million for the three months ended December 31, 2025, compared to $9.1 million for the same period in 2024. For the twelve months ended December 31, 2025, general and administrative expenses were $41.5 million, compared to $43.7 million for the same period in 2024. The year-over-year change was primarily due to decreased spend on personnel-related costs.

The net loss for the three months ended December 31, 2025, was $38.7 million, or $0.29 per share, compared to a net loss of $30.8 million, or $0.32 per share, in the same period in 2024. For the twelve months ended December 31, 2025, the net loss was $101.6 million, or $0.87 per share, compared to a net loss of $130.3 million, or $1.19 per share, in the same period in 2024.

Tango Therapeutics' CEO, Malte Peters, expressed a clear focus on execution and building on the significant progress achieved across the company's development portfolio in 2025. The lead clinical program, vopimetostat, continues to demonstrate best-in-class potential, with plans to initiate a pivotal study for vopimetostat monotherapy in 2L mtap-del pancreatic cancer in 2026. Strong enrollment continues in the combination study with Revolution Medicines’ ras(on) inhibitors, and the company is encouraged by the early safety and efficacy data.

The company also provided several upcoming expected milestones, including initial phase 1/2 safety and efficacy data from combination trials with vopimetostat + daraxonrasib and vopimetostat + zoldonrasib (Revolution Medicines) in 2026, vopimetostat monotherapy phase 1/2 clinical data lung cancer update in 2026, and the start of the vopimetostat monotherapy 2L pancreatic cancer pivotal study in 2026.

Tango Therapeutics also announced corporate updates, including the appointment of Philippe Serrano, Pharm.D., as its chief regulatory officer, CEO succession, and the expansion of its board of directors with the appointment of Mr. Sung Lee.

As a result of these announcements, the company's shares have moved 11.29% on the market, and are now trading at a price of $13.01. Check out the company's full 8-K submission here.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.

IN FOCUS